p53 suppresses carcinoma progression by inhibiting mTOR pathway activation

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

mTORC1 and p53

(2012) Paul Hasty et al.   CELL CYCLE

New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy

(2012) M. Dong et al.   CLINICAL CANCER RESEARCH

Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases

(2012) A. Tamburrino et al.   CLINICAL CANCER RESEARCH

Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma

(2012) Madson Q. Almeida et al.   CURRENT OPINION IN ONCOLOGY

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Cooperation between Rb and Arf in suppressing mouse retinoblastoma

(2012) Karina Conkrite et al.   JOURNAL OF CLINICAL INVESTIGATION

The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions

(2011) Elizabeth M. Matthew et al.   CELL CYCLE

Everolimus is an active agent in medullary thyroid cancer: a clinical andin vitrostudy

(2011) A. Faggiano et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Mammalian Target of Rapamycin Pathway Activation Is Associated to RET Mutation Status in Medullary Thyroid Carcinoma

(2011) Ida Rapa et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas

(2011) Margarida M. Moura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas

(2011) Maria A. Kouvaraki et al.   SURGERY

Medullary thyroid cancer: an update of new guidelines and recent developments

(2010) Leslie S Wu et al.   CURRENT OPINION IN ONCOLOGY

Medullary, Anaplastic, and Metastatic Cancers of the Thyroid

(2010) Susan C. Pitt et al.   SEMINARS IN ONCOLOGY

The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein

(2010) Zhaohui Feng et al.   TRENDS IN CELL BIOLOGY

Retinoblastoma Family Proteins Have Distinct Functions in Pulmonary Epithelial Cells In vivo Critical for Suppressing Cell Growth and Tumorigenesis

(2009) D. S. Simpson et al.   CANCER RESEARCH

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets

(2009) Aniello Cerrato et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells

(2009) Simona Grozinsky-Glasberg et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Current Management of Medullary Thyroid Cancer

(2008) R. S. Sippel et al.   ONCOLOGIST